
Grünenthal licenses exclusive Canadian rights to testosterone replacement therapy Nebido® to Apotex5.2.2026 16:03:03 CET | news aktuell GmbH | Press Release
Aachen, Germany & Toronto, Canada, February 5, 2026 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to Nebido® (testosterone undecanoate), a long-acting injectable therapy indicated for the treatment of male hypogonadism (testosterone deficiency).[1] [1] https://www.medicines.org.uk/emc/product/14631/smpc
















